Drug Patents owned by Sanofi Aventis Us

1. Drug name - AUBAGIO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6794410 SANOFI AVENTIS US Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide for treating multiple sclerosis Sep, 2026

(3 years from now)

US6794410

(Pediatric)

SANOFI AVENTIS US Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide for treating multiple sclerosis Mar, 2027

(4 years from now)

US8802735 SANOFI AVENTIS US (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability Sep, 2030

(7 years from now)

US8802735

(Pediatric)

SANOFI AVENTIS US (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability Mar, 2031

(8 years from now)

US9186346 SANOFI AVENTIS US Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients Feb, 2034

(11 years from now)

US9186346

(Pediatric)

SANOFI AVENTIS US Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients Aug, 2034

(11 years from now)

Drugs and Companies using TERIFLUNOMIDE ingredient

Treatment: Treatment of patients with relapsing forms of multiple sclerosis; Treatment of patients with relapsing forms of multiple sclerosis while managing the risk of teriflunomide and rosuvastatin interaction by limiting the rosuvastatin dose to no more than 10mg and/or administering about half the normal dose

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
7MG TABLET;ORAL Prescription
14MG TABLET;ORAL Prescription

2. Drug name - JEVTANA KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7241907 SANOFI AVENTIS US Acetone solvate of dimethoxy docetaxel and its process of preparation
Dec, 2025

(3 years from now)

CN1849311A SANOFI AVENTIS US Dimethoxy Docetaxel Acetone Compound And Preparation Method Thereof
Sep, 2024

(1 year, 11 months from now)

CN100429207C SANOFI AVENTIS US Dimethoxy Docetaxel Acetone Compound And Preparation Method Thereof
Sep, 2024

(1 year, 11 months from now)

IN200600944P4 SANOFI AVENTIS US Dimethoxy Docetaxel Acetone Solvate Et Method For The Preparation Thereof
Sep, 2024

(1 year, 11 months from now)

IN253669B SANOFI AVENTIS US A Process For The Preparation Of Acetone Solvate Of Dimethoxy Docetaxel
Sep, 2024

(1 year, 11 months from now)

EP1667986B1 SANOFI AVENTIS US Dimethoxy Docetaxel Acetone Solvate Et Method For The Preparation Thereof
Mar, 2026

(3 years from now)

EP1667986A1 SANOFI AVENTIS US Dimethoxy Docetaxel Acetone Solvate Et Method For The Preparation Thereof
Mar, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7241907

(Pediatric)

SANOFI AVENTIS US Acetone solvate of dimethoxy docetaxel and its process of preparation Jun, 2026

(3 years from now)

US10583110 SANOFI AVENTIS US Antitumoral use of cabazitaxel Oct, 2030

(8 years from now)

US8927592 SANOFI AVENTIS US Antitumoral use of cabazitaxel Oct, 2030

(8 years from now)

US10716777 SANOFI AVENTIS US Antitumoral use of cabazitaxel Oct, 2030

(8 years from now)

US8927592

(Pediatric)

SANOFI AVENTIS US Antitumoral use of cabazitaxel Apr, 2031

(8 years from now)

Drugs and Companies using CABAZITAXEL ingredient

Treatment: Increasing survival in metastatic castration-resistant prostate cancer patients previously treated with docetaxel by administering as a 3 week cycle cabazitaxel after 5 mg dexchlorpheniramine, 8 mg dexamethasone, and an h2-agonist; Increasing survival in mcrpc patients previously treated with docetaxel by administering cabazitaxel in combination with prednisone or prednisolone after a premedication regimen that includes an antihistamine, a corticosteroid, and an h2-antagonist; Increasing survival in metastatic castration-resistant prostate cancer patients previously treated with docetaxel by administering 20 to 25 mg/m2 cabazitaxel after a premedication regimen that includes an h2-antagonist

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
60MG/1.5ML (40MG/ML) SOLUTION;INTRAVENOUS Prescription

3. Drug name - MULTAQ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8410167 SANOFI AVENTIS US Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality Apr, 2029

(6 years from now)

US9107900 SANOFI AVENTIS US Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of morality Apr, 2029

(6 years from now)

US8602215 SANOFI AVENTIS US Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation Jun, 2031

(8 years from now)

Drugs and Companies using DRONEDARONE HYDROCHLORIDE ingredient

Treatment: Reduction in risk of hospitalization in patients with a history of paroxysmal or persistent af without severe heart failure and with one or more risk factors by administration twice a day with morning and evening meals; treatment of patients with a history of paroxysmal or persistent af without severe heart failure and with one or more risk factors by administration twice a day with morning and evening meals; Reduction in risk of hospitalization in patients with stable nyha class iii heart failure and a history of paroxysmal or persistent af and with one or more risk factors by administration twice a day with morning and evening meals; reduction in risk of hospitalization in patients with coronary heart disease and a history of paroxysmal or persistent af and with one or more risk factors by administration twice a day with morning and evening meals; Management of risk of dronedarone/beta-blocker interaction in patients in sinus rythm with a history of paroxysmal or persistent af

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 400MG BASE TABLET;ORAL Prescription

4. Drug name - OFORTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7148207 SANOFI AVENTIS US Oral fludara of high-purity formulation with quick release of active ingredient Dec, 2022

(2 months from now)

Drugs and Companies using FLUDARABINE PHOSPHATE ingredient

Treatment: Treatment of patients with b-cell chronic lymphocytic leukemia (cll)

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
10MG TABLET;ORAL Discontinued

availability in other generic markets.

Click on the highlighted region to filter.